Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

treatment-resistant depression

This page shows the latest treatment-resistant depression news and features for those working in and with pharma, biotech and healthcare.

J&J gets EU approval for depression nasal spray Spravato

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing. Johnson &Johnson can market its treatment-resistant depression drug Spravato on both sides of the Atlantic, now that the EMA has followed ... Approximately half of all Spravato patients achieved

Latest news

  • Sage slides off a MOUNTAIN as depression drug flunks trial Sage slides off a MOUNTAIN as depression drug flunks trial

    SAGE-217 is an oral follow-up to Sage’s  Zulresso (brexanolone) for postpartum depression (PPD), which was approved by the FDA in March and is delivered by a ... that is used as an add-on to standard drugs for treatment-resistant depression.

  • J&J’s ponesimiod tops Aubagio in head-to-head MS trial J&J’s ponesimiod tops Aubagio in head-to-head MS trial

    The company does however have a resurgent central nervous system (CNS) therapeutic category following the approval of Spravato(esketamine), a nasal spray for treatment-resistant depression that J&J reckons can

  • Stung by critics, J&J says antidepressant Spravato saves money Stung by critics, J&J says antidepressant Spravato saves money

    Responds to ICER cost effectiveness ruling. Johnson &Johnson insists its nasal spray antidepressant Spravato can reduce the cost of caring for treatment-resistant depression (TRD) compared to oral drugs, in a ... label prescription and coverage of a

  • J&J’s Spravato breaks depression drought at FDA J&J’s Spravato breaks depression drought at FDA

    The FDA has approved Johnson &Johnson’s Spravato for treatment-resistant depression, making it the first new-mechanism antidepressant to be licensed in decades. ... At the moment the only FDA-approved drug for treatment-resistant depression is Eli

  • FDA panel backs J&J’s new-class antidepressant FDA panel backs J&J’s new-class antidepressant

    Johnson &Johnson could be just weeks away from approval of the first new drug class for depression in decades, giving a new option for patients with severe, treatment-resistant symptoms. ... The agency has awarded J&J two breakthrough designations for

More from news
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

  • War on drugs: the use of controlled substances in medicine War on drugs: the use of controlled substances in medicine

    the treatment of medical conditions; medical conditions such as mental disorders which are now among the leading causes of ill-health and disability worldwide. ... Ketamine has shown efficacy in the treatment of mental health conditions with the FDA

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...

Quick links